A rangy man stepped to the microphone at Sahuarita’s town hall and started raging about “gingers” — red-haired people. “We got to choke every ginger in town,” said the man, Mark Brown. “We can’t have ...
GSK has become the latest drugmaker to run into difficulties in developing a drug targeting the immune checkpoint receptor TIM-3, after its cobolimab candidate flunked a phase 3 trial in lung cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback